How do the authors account for the possibility that FOXO3a activation by NBCs may exert pro-survival effects in certain tumor contexts, particularly under metabolic or therapeutic stress? Were any of the reviewed studies evaluated for compensatory survival pathways or resistance phenotypes that could be exacerbated by FOXO3a-driven transcriptional activity?
